Astria Therapeutics Inc

Astria Therapeutics — Catabasis Pharmaceuticals — Corporate Update (June 2017)

28 slides from Astria Therapeutics's corporate update, Jun 19, 2017

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding our expectations and beliefs about our business, future financial and operating performance, clinical trial plan

  2. Slide 2: Advancing Rare Disease Pipeline: Preparing for Phase 3 Trial in Duchenne Muscular Dystrophy

    Advancing Rare Disease Pipeline: Preparing for Phase 3 Trial in Duchenne Muscular Dystrophy Edasalonexent completed placebo-controlled Phase 2 MoveDMD trial – – – Oral inhibitor of NF-KB for all patients with DMD regardless of mutation Open-label extension results expected in Q3 2017 Phase 3 trial p

  3. Slide 3: Pipeline of Product Candidates in Rare Diseases

    Pipeline of Product Candidates in Rare Diseases Product Candidate (Pathway) Discovery Preclin Phase 1 Phase 2 Phase 3 • • Phase 2 complete Open-label extension results in Q3 2017 Phase 3 plan H2 2017 Edasalonexent CAT-1004 (NF-KB) Duchenne muscular dystrophy • Edasalonexent CAT-1004 (NF-KB) Addition

  4. Slide 4: Pipeline of Product Candidates in Rare Diseases

    Pipeline of Product Candidates in Rare Diseases Product Candidate (Pathway) Edasalonexent CAT-1004 (NF-KB) Edasalonexent CAT-1004 (NF-KB) CAT-5571 (Autophagy) CAT-4001 (Nrf2/NF-kB) Aeatabasis Discovery Preclin Phase 1 Phase 2 Phase 3 + Phase 2 complete + Open-label extension results in Q3 2017 + Pha

  5. Slide 5: Duchenne Muscular Dystrophy: Preserving Function Is the Goal of Treatment

    Duchenne Muscular Dystrophy: Preserving Function Is the Goal of Treatment DMD is a rare recessive X-linked genetic disorder characterized by dystrophin deficiency in muscle tissue and subsequent chronic activation of NF-KB that results in muscle degeneration and prevents muscle regeneration Overall

  6. Slide 6: DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility

    DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility Milestones Typical DMD Disease Progression Impaired ability to hop run jump Loss of rise from floor Loss of mobility and function Loss of stair climb Loss of ambulation Loss of upper limb function Ventilation D

  7. Slide 7: Steroids Are the Mainstay of Current DMD Treatment Because They Delay Loss of Function

    Steroids Are the Mainstay of Current DMD Treatment Because They Delay Loss of Function 1980s – Present Glucocorticoids/Steroids Steroids delay loss of function and prolong ambulation time and lifespan 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 However, steroids are associated Logrank P=0.0005 with

  8. Slide 8: Edasalonexent (CAT-1004) Program

    Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-KB for the treatment of Duchenne muscular dystrophy 9

  9. Slide 9: Edasalonexent: Potential to Slow Disease Progression for All Boys with DMD

    Edasalonexent: Potential to Slow Disease Progression for All Boys with DMD Investigational disease-modifying product candidate for all patients with DMD regardless of mutation Oral inhibitor of NF-KB, a protein that is chronically activated in DMD and drives muscle degeneration and suppresses muscle

  10. Slide 10: DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility

    DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility Milestones Typical DMD Disease Progression Impaired ability to hop run jump Edasalonexent goal: Slow rate of decline Loss of rise from floor Loss of stair climb Loss of ambulation Loss of upper limb function Ve

  11. Slide 11: Edasalonexent Inhibits Activated NF-kB, Slows Muscle Degeneration, and Stimulates Muscle Regeneration

    Edasalonexent Inhibits Activated NF-KB, Slows Muscle Degeneration, and Stimulates Muscle Regeneration MECHANICAL STRESS IVATED INJURED FIBERS NF-kB PROMOTES SUPPRESSES DRIVES MUSCLE DEGENERATION INFLAMMATION MUSCLE + FIBROSIS REGENERATION Hammers, et al. JCI Insight 2016 1(21): e90341 12 ACT

  12. Slide 12: Edasalonexent Inhibits Activated NF-kB, Slows Muscle Degeneration, and Stimulates Muscle Regeneration

    Edasalonexent Inhibits Activated NF-KB, Slows Muscle Degeneration, and Stimulates Muscle Regeneration MECHANICAL STRESS INJURED FIBERS EDASALONEXENT DECREASES INFLAMMATION + FIBROSIS STIMULATES MUSCLE REGENERATION SLOWS MUSCLE DEGENERATION Hammers, et al. JCI Insight 2016 1(21): e90341 13 ACTIVATED

  13. Slide 13: MoveDMD Phase 2 Demonstrated Favorable Delay in Loss of Function

    MoveDMD Phase 2 Demonstrated Favorable Delay in Loss of Function in Critical Function and Mobility Parameters TWO PRE-SPECIFIED ANALYSES Placebo-Controlled Crossover Edasa Edasa Pooled (n=20) Edasa Pooled (n=12) 67 mg/kg/day (n=10) + + - + + + + - + + + + + + +* 10-meter walk/run 4-stair Climb Time

  14. Slide 14: Composite Score for Phase 2 Functional Assessments

    Composite Score for Phase 2 Functional Assessments Edasalonexent Preserves Function by Slowing Rate of Decline Max. possible score 5 p < 0.05 0 Min. possible score - 5 Placebo Edasalonexent (n=11) (n=20) Individual scores for 4-stair climb, 10-meter walk/run, time to stand, NSAA and PODCI were poole

  15. Slide 15: Timed Function Test: 10-meter Walk/Run Speed: Rate of Loss of Function Slowed

    Timed Function Test: 10-meter Walk/Run Speed: Rate of Loss of Function Slowed Placebo-Controlled Crossover 0 . 0 0 5 0 . 0 0 5 0 . 0 0 0 0 . 0 0 0 - 0 . 0 0 5 - 0 . 0 0 5 - 0 . 0 1 0 - 0 . 0 1 0 p NS - 0 . 0 1 5 - 0 . 0 1 5 - 0 . 0 2 0 - 0 . 0 2 0 Placebo (n=11) Edasalonexent Placebo (n=12) Edasalon

  16. Slide 16: Timed Function Test: 4-stair Climb: Rate of Loss of Function Slowed to No Decline

    Timed Function Test: 4-stair Climb: Rate of Loss of Function Slowed to No Decline Placebo-Controlled Crossover 0 . 0 4 0 . 0 4 0 . 0 2 0 . 0 2 0 . 0 0 0 . 0 0 - 0 . 0 2 - 0 . 0 2 - 0 . 0 4 - 0 . 0 4 Placebo (n=11) Edasalonexent Placebo (n=12) Edasalonexent (n=12) (n=20) • There was a ~5% decline in

  17. Slide 17: Timed Function Test: Time to Stand: Rate of Loss of Function Slowed

    Timed Function Test: Time to Stand: Rate of Loss of Function Slowed Placebo-Controlled Crossover 0 . 0 2 00 ..00 00 0 0 . 0 1 --0 . 0 01 1 0 . 0 0 - 0 . 0 1 --00 ..00 02 2 - 0 . 0 2 - -00. .00033 - 0 . 0 3 Placebo (n=11) Edasalonexent Placebo (n=12) Edasalonexent (n=12) (n=20) • There was a ~0.4% de

  18. Slide 18: Global Functional Assessment: North Star Ambulatory Assessment

    Global Functional Assessment: North Star Ambulatory Assessment: Rate of Decline in Score Slowed with Positive Improvement Seen Placebo-Controlled Crossover 2 2 1 1 0 0 - 1 - 1 - 2 - 2 - 3 Placebo (n=11) Edasalonexent (n=20) Placebo (n=12) Edasalonexent (n=12) •The change in North Star Ambulatory Ass

  19. Slide 19: Global Functional Assessment: PODCI: Significant Improvements

    Global Functional Assessment: Pediatric Outcomes Data Collection Instrument (PODCI): Significant Improvements Placebo-Controlled Crossover pP <=00..0015 8 8 4 4 0 0 - 4 - 4 - 8 - 8 Placebo (n=11) Edasalonexent Placebo (n=12) Edasalonexent (n=12) (n=20) •The change in the PODCI was numerically better

  20. Slide 20: Key Takeaways from Phase 2 Data

    Key Takeaways from Phase 2 Data Reduction in rate of functional decline in MoveDMD Phase 2 – Reduction in rates of decline in well established timed function tests – Improvements in scores on validated global functional assessments No safety signals identified and well-tolerated Functional improveme

  21. Slide 21: Edasalonexent Increases Dystrophin Expression in Combination with Exon-Skipping

    Edasalonexent Increases Dystrophin Expression in Combination with Exon-Skipping Exon Skip Saline Exon Skip + Edasa 10 Data shown from a preclinical mouse model of DMD Sarepta and Catabasis (Unpublished observations) *p<0.05 5 Exon Skip Exon Skip + Edasa wild type/saline mdx/saline mdx/edasa mdx/M23D

  22. Slide 22: Edasalonexent Increases Dystrophin Expression in Combination with Exon-Skipping

    Edasalonexent Increases Dystrophin Expression in Combination with Exon-Skipping Exon Skip saline maxisline _—_mfedasa__—_mis230_ macM4220/e4959 M230: exon skipping specifi for dx; Nelsa Estrela, Sarepta (Unpublished observations) ANeatabasis Exon Skip + Edasa Quadriceps Data show ‘% Wild-Type Levels

  23. Slide 23: The Intersection of Pathway Biology and the SMART Linker Platform

    The Intersection Of Pathway Biology and the SMART Linker Platform BIFUNCTIONAL CONJUGATES of known bioactives engineered with proprietary, enzyme-cleavable small chemical linkers CELLULAR UPTAKE by endocytosis SMART linker conjugate Outside cell Inside cell (“SMART linkers”) Enzyme-specific cleavage

  24. Slide 24: CAT-5571: Breaking the Spiral of Cystic Fibrosis Progression

    CAT-5571: Breaking the Spiral of Cystic Fibrosis Progression Obstruction CFTR Dysfunction Respiratory Tract Infection Obstruction Structural damage Respiratory Tract Infection Obstruction Bronchiectasis Respiratory Tract Infection Inflammation Pulmonary Insufficiency Inflammation Respiratory Failure

  25. Slide 25: CAT-5571 Reduces Pulmonary Infection and Inflammation and Increases CFTR Function

    CAT-5571 Reduces Pulmonary Infection and Inflammation and Increases CFTR Function in Presence of F508del CFTR CAT-5571 reduces pulmonary P. aeruginosa infection and inflammation in mice with delF508 mutation P u l m o n a r y B a c t e r i a l L o a d P u l m o n a r y N e u t r o p h i l l i a 1 ´

  26. Slide 26: Catabasis in 2017: Anticipated Events and Priorities

    Catabasis in 2017: Anticipated Events and Priorities Report results from the open-label extension of the MoveDMD trial in Q3 2017 Announce Phase 3 trial plan for edasalonexent in DMD in H2 2017 Continue IND-enabling activities to initiate Phase 1 trial for CAT-5571 in 2018 Continue ongoing preclinic

  27. Slide 27: Catabasis Pharmaceuticals

    Catabasis Pharmaceuticals Corporate Update June 19, 2017

  28. Slide 28: Catabasis Pharmaceuticals

    WN catabasis Catabasis Pharmaceuticals Corporate Update June 19, 2017

Catabasis Pharmaceuticals — Corporate Update (June 2017) on 6ix